For obese individuals, prevalence of current marijuana use is 35% lower than for non-obese individuals on average. The adjusted odds of current or daily marijuana use are significantly lower among obese versus non-obese adults (0.68 and 0.69, respectively).
Cancer Patients With Medical Marijuana Cards Less Likely to Receive Excess Antiemetics, Arkansas Study Finds
Compared with non-MMJ cardholders, MMJ cardholders were less likely to experience antiemetic overuse (aOR: 0.76, p < 0.001). Further investigation into the use, effectiveness, and safety of cannabis for CINV mitigation is needed to inform patient and provider decision-making.
Marijuana Users Have Lower Obesity Rates, But Does the Drug Cause This?
For obese individuals, prevalence of current marijuana use is 35% lower than for non-obese individuals on average. Lower prevalence of marijuana use in obese individuals is consistently observed across the levels of certain demographic variables, employment status, tobacco smoking history, marijuana legalization status, and certain medical conditions.
Cannabis Users Spend Less Time in Epilepsy Monitoring Units—But the Reasons Are Unclear
Cannabis use was associated with a 0.9 day LOS reduction compared to non-users. Among patients admitted for spell classification, event capturability was 18.1% higher in cannabis users. Additionally, cannabis users had increased prevalence of psychosocial comorbidities: 12.6% reported physical abuse, 11.1% sexual abuse, and 10.2% mental abuse.
Cannabis stigma and symptom management considerations in cancer survivors: a mixed-methods exploration of patient perspectives.
This study aims to assess for indications of stigma and attitudes toward cannabis among cancer survivors (CS) who use or consider the use of cannabis. This s…
Medicinal Cannabis Prescription Before an Inpatient Psychiatric Admission: A Retrospective Observational Audit.
Prescribing of medicinal cannabis has expanded in Australia; however, evidence for benefit in psychiatric populations is limited. The goal of this study was …
Leveraging the national cancer institute’s collaborative efforts to understand the benefits and harms of cannabis use among individuals with cancer.
Cannabis use for symptom management among patients with cancer has increased significantly in recent years, with many reporting benefits for pain, anxiety, s…
GLP-1 Receptor Agonist: Why Some Patients Don’t Respond
GLP-1 Clinical Relevance #56Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyType 2 DiabetesGLP-1 Receptor AgonistEndocrinologyAdults with ObesityTreatment Response VariabilityGenetic MechanismSemaglutide EfficacyIndividual...
GLP-1 Receptor Agonist Benefits in Cardiac Interventions
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialObservational StudyCardiovascular InterventionTirzepatideCardiologyAdults with ObesityProcedural OutcomesAppetite RegulationTAVR and PCIGLP-1 Receptor AgonistPerioperative...
GLP-1 Cardiovascular Outcomes: Clinical Evidence & Safety
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyCardiovascular OutcomesTirzepatideCardiologyAdults with ObesityCardiovascular Mortality ReductionGLP-1 Receptor Agonist MechanismWomen’s Health OutcomesMidlife...